4 results on '"Syed, Najeeb A"'
Search Results
2. Mutational landscape of inflammatory breast cancer
- Author
-
Bertucci, François, Lerebours, Florence, Ceccarelli, Michele, Guille, Arnaud, Syed, Najeeb, Finetti, Pascal, Adélaïde, José, Van Laere, Steven, Goncalves, Anthony, Viens, Patrice, Birnbaum, Daniel, Mamessier, Emilie, Callens, Céline, and Bedognetti, Davide
- Published
- 2024
- Full Text
- View/download PDF
3. Genetic architecture of congenital hypogonadotropic hypogonadism: insights from analysis of a Portuguese cohort.
- Author
-
Carriço, Josianne Nunes, Gonçalves, Catarina Inês, Al-Naama, Asma, Syed, Najeeb, Aragüés, José Maria, Bastos, Margarida, Fonseca, Fernando, Borges, Teresa, Pereira, Bernardo Dias, Pignatelli, Duarte, Carvalho, Davide, Cunha, Filipe, Saavedra, Ana, Rodrigues, Elisabete, Saraiva, Joana, Ruas, Luisa, Vicente, Nuno, Martins, João Martin, Lages, Adriana De Sousa, and Oliveira, Maria João
- Subjects
HEREDITY ,DNA copy number variations ,GENETIC testing ,PORTUGUESE people ,GENE frequency ,KALLMANN syndrome - Abstract
STUDY QUESTION What is the contribution of genetic defects in Portuguese patients with congenital hypogonadotropic hypogonadism (CHH)? SUMMARY ANSWER Approximately one-third of patients with CHH were found to have a genetic cause for their disorder, with causal pathogenic and likely pathogenic germline variants distributed among 10 different genes; cases of oligogenic inheritance were also included. WHAT IS KNOWN ALREADY CHH is a rare and genetically heterogeneous disorder characterized by deficient production, secretion, or action of GnRH, LH, and FSH, resulting in delayed or absent puberty, and infertility. STUDY DESIGN, SIZE, DURATION Genetic screening was performed on a cohort of 81 Portuguese patients with CHH (36 with Kallmann syndrome and 45 with normosmic hypogonadotropic hypogonadism) and 263 unaffected controls. PARTICIPANTS/MATERIALS, SETTING, METHODS The genetic analysis was performed by whole-exome sequencing followed by the analysis of a virtual panel of 169 CHH-associated genes. The main outcome measures were non-synonymous rare sequence variants (population allele frequency <0.01) classified as pathogenic, likely pathogenic, and variants of uncertain significance (VUS). MAIN RESULTS AND THE ROLE OF CHANCE A genetic cause was identified in 29.6% of patients. Causal pathogenic and likely pathogenic variants were distributed among 10 of the analysed genes. The most frequently implicated genes were GNRHR , FGFR1 , ANOS1 , and CHD7. Oligogenicity for pathogenic and likely pathogenic variants was observed in 6.2% of patients. VUS and oligogenicity for VUS variants were observed in 85.2% and 54.3% of patients, respectively, but were not significantly different from that observed in controls. LARGE SCALE DATA N/A. LIMITATIONS, REASONS FOR CAUTION The identification of a large number of VUS presents challenges in interpretation and these may require reclassification as more evidence becomes available. Non-coding and copy number variants were not studied. Functional studies of the variants were not undertaken. WIDER IMPLICATIONS OF THE FINDINGS This study highlights the genetic heterogeneity of CHH and identified several novel variants that expand the mutational spectrum of the disorder. A significant proportion of patients remained without a genetic diagnosis, suggesting the involvement of additional genetic, epigenetic, or environmental factors. The high frequency of VUS underscores the importance of cautious variant interpretation. These findings contribute to the understanding of the genetic architecture of CHH and emphasize the need for further studies to elucidate the underlying mechanisms and identify additional causes of CHH. STUDY FUNDING/COMPETING INTEREST(S) This research was funded by the Portuguese Foundation for Science and Technology (grant numbers PTDC/SAU-GMG/098419/2008, UIDB/00709/2020, CEECINST/00016/2021/CP2828/CT0002, and 2020.04924.BD) and by Sidra Medicine—a member of the Qatar Foundation (grant number SDR400038). The authors declare no competing interests. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Evolution of Metastases in Space and Time under Immune Selection
- Author
-
Gabriela Bindea, Lucie Lafontaine, Yves Humblet, Anne Jouret-Mourin, Najeeb Syed, Catherine Hubert, Alex Kartheuser, Mihaela Angelova, Daniela Bruni, Jérôme Galon, Michele Ceccarelli, Davide Bedognetti, Marc Van den Eynde, Bénédicte Buttard, Bernhard Mlecnik, Angela Vasaturo, Francesco M. Marincola, Erwan Morgand, Tessa Fredriksen, Angelova, Mihaela, Mlecnik, Bernhard, Vasaturo, Angela, Bindea, Gabriela, Fredriksen, Tessa, Lafontaine, Lucie, Buttard, Bénédicte, Morgand, Erwan, Bruni, Daniela, Jouret-Mourin, Anne, Hubert, Catherine, Kartheuser, Alex, Humblet, Yve, Ceccarelli, Michele, Syed, Najeeb, Marincola, Francesco M., Bedognetti, Davide, Van den Eynde, Marc, and Galon, Jérôme
- Subjects
0301 basic medicine ,Genetics and Molecular Biology (all) ,recurrence ,Colorectal cancer ,CD3 ,medicine.medical_treatment ,immunoscore ,Somatic evolution in cancer ,Biochemistry ,General Biochemistry, Genetics and Molecular Biology ,Metastasis ,immunoediting ,03 medical and health sciences ,clonal ,0302 clinical medicine ,Immune system ,Lymphocytes, Tumor-Infiltrating ,Leukemic Infiltration ,Neoplasms ,medicine ,Tumor Microenvironment ,Humans ,Neoplasm Metastasis ,Models, Statistical ,biology ,Cancer ,T cell ,Immunotherapy ,medicine.disease ,microenvironment ,Tumor Burden ,030104 developmental biology ,Immunoediting ,030220 oncology & carcinogenesis ,Cancer research ,biology.protein ,metastasi ,immunotherapy ,heterogeneity ,mutation - Abstract
We examined how the immune microenvironment molds tumor evolution at different metastatic organs in a longitudinal dataset of colorectal cancer. Through multiplexed analyses, we showed that clonal evolution patterns during metastatic progression depend on the immune contexture at the metastatic site. Genetic evidence of neoantigen depletion was observed in the sites with high Immunoscore and spatial proximity between Ki67+ tumor cells and CD3+ cells. The immunoedited tumor clones were eliminated and did not recur, while progressing clones were immune privileged, despite the presence of tumor-infiltrating lymphocytes. Characterization of immune-privileged metastases revealed tumor-intrinsic and tumor-extrinsic mechanisms of escape. The lowest recurrence risk was associated with high Immunoscore, occurrence of immunoediting, and low tumor burden. We propose a parallel selection model of metastatic progression, where branched evolution could be traced back to immune-escaping clones. The findings could inform the understanding of cancer dissemination and the development of immunotherapeutics.
- Published
- 2018
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.